REIKO ARITA, IZUMI MINOURA, NAOYUKI MORISHIGE, RIKA SHIRAKAWA, SHIMA FUKUOKA, KEI ASAI, TATEKI GOTO, TAKAHIRO IMANAKA, AND MASATSUGU NAKAMURA PURPOSE: To develop and validate grading scales for meibomian gland dysfunction (MGD) that allow consistent diagnosis of MGD and are suitable for clinical studies.
T HE TEAR FILM THAT COVERS THE OCULAR SURFACE is protected from evaporation by a thin layer of lipid secreted by the meibomian glands. 1 Meibomian gland dysfunction (MGD) is one of the most common disorders encountered in ophthalmic clinics and is now recognized as a major cause of dry eye syndrome. [2] [3] [4] [5] It can result in tear film instability, damage to the ocular surface epithelium, chronic blepharitis, and contact lens intolerance. [6] [7] [8] [9] [10] MGD is commonly characterized by a chronic, diffuse abnormality of meibomian glands, terminal duct obstruction, and qualitative or quantitative changes in the glandular secretion. 11 The key signs of MGD are meibomian gland dropout, altered meibomian gland secretion, and changes in morphology of the lid margin. The lid margin abnormalities may become detectable with a slit-lamp microscope as the disease progresses. 12 Lid margin findings and meibomian gland morphology are therefore important for diagnosis of MGD. Diagnosis and quantification of MGD thus require assessment of symptoms, altered meibomian gland secretion, changes in lid morphology, and meibomian gland dropout. 12 Evaluation of meibomian gland expressibility as a dynamic process is also important. Assessment of the efficacy of treatment for MGD requires precise evaluation of changes in lid morphology, meibomian gland dropout, and meibomian gland expressibility. The ability to perform an objective evaluation of MGD based on photographs would be useful as a standardized procedure for multicenter clinical trials.
Grading scales for diagnosis of MGD have been proposed and adopted in clinical practice. [13] [14] [15] [16] [17] [18] These scales are based on assessment of lid margin findings [13] [14] [15] or of meibomian glands, with the latter scales being based on the proportion of meibomian glands showing dropout in only the lower tarsal plate 16, 17 or on the number of whole glands and proportion of partial glands. 18 The application of these existing scales to the clinic is difficult, however, because there are many grading subdivisions for each sign or their targets are limited to the lower eyelids. Moreover, information on grading reliability has been available for only a few scales. There is thus still an unmet need for reliable and widely adoptable grading scales based on evaluation of both upper and lower eyelids for the consistent diagnosis of MGD.
We have now developed new grading scales for MGD that can be used by ophthalmologists without special experience, and we have performed a validation study to confirm the robustness of these scales. We propose that these grading scales are suitable for the diagnosis of MGD or for its evaluation in clinical studies.
METHODS

STUDY DESIGN AND TARGET POPULATION:
This study was conducted at The University of Tokyo Hospital, Itoh Clinic (Saitama City, Saitama, Japan), and Maeda Ophthalmic Clinic (Aizuwakamatsu City, Fukushima, Japan). MGD patients and control subjects were randomly enrolled from outpatients who visited the 3 medical facilities from December 4, 2012 to December 7, 2013. The study adhered to the tenets of the Declaration of Helsinki and was prospectively approved by the Institutional Review Board of Tokyo University School of Medicine. All subjects provided written informed consent before entry into the study.
The MGD patients were aged > _20 years and were diagnosed on the basis of previously described criteria 19, 20 : (1) at least 1 symptom, such as ocular fatigue, discharge, foreign body sensation, dryness, uncomfortable sensation, sticky sensation, pain, epiphora, itching, redness, heavy sensation, glare, excessive blinking, burning sensation, and ocular discomfort on arising; (2) at least 1 abnormal lid margin finding, such as vascular engorgement, anterior or posterior replacement of the mucocutaneous junction, and irregular lid margin; and (3) plugged meibomian gland orifices and poor meibum expressibility in the target eye. The control subjects had never been diagnosed with blepharitis or MGD, were aged > _20 years, and had no history of contact lens wear or eye surgery. Individuals with severe systemic illness or with squamous Conjunctival staining was scored 0-3 for each of the nasal and temporal conjunctiva and then summed. cell debris (collarette) around the base of the eyelashes were excluded.
CLINICAL ASSESSMENT AND IMAGE COLLECTION: One eye was selected as the target eye in each subject. Complications, history of contact lens wear or eye surgery, the presence of ocular allergy, and concomitant medications were noted as background information. The subjects were assessed for lid margin and meibomian gland findings, as well as for their experience of subjective symptoms.
Lid margin findings were evaluated for the upper and lower eyelids with the use of a slit-lamp microscope. Telangiectasia was assessed on a scale from 0 to 3: 0 ¼ no findings; 1 ¼ mild telangiectasia; 2 ¼ moderate telangiectasia or redness; 3 ¼ severe telangiectasia or redness. Mucocutaneous junction was assessed on a scale from 0 to 3: 0 ¼ Marx line (ML) courses on the skin side of the meibomian orifice (MO) line and does not touch MOs at all; 1 ¼ parts of ML touch MOs; 2 ¼ ML courses through MOs; 3 ¼ ML courses along the eyelid margin side of MOs. 21 Irregularity, plugging, foaming, and thickness were assessed on a scale from 0 to 2: 0 ¼ no findings; 1 ¼ mild findings; 2 ¼ severe findings.
Corneal and conjunctival staining were scored from 0 to 9. 22 The tear film breakup time (BUT) was measured 3 times consecutively after the instillation of fluorescein, and the mean value was adopted. Tear fluid production was evaluated with the Schirmer test without anesthesia.
Meibomian glands were evaluated for the upper and lower lids with the use of a noncontact meibography system attached to a slit-lamp microscope. Partial or complete loss of meibomian glands was scored on a scale from 0 to 3 (meiboscore), as described previously. 23 The extent of meibomian gland dropout was determined on a scale from 0 to 2 based on the number of affected glands: 0 ¼ none; 1 ¼ small number; 2 ¼ large number.
The degree of ease with which meibum could be expressed at the central area of both upper and lower eyelid was evaluated semiquantitatively on a scale from 0 to 3: 0 ¼ clear meibum readily expressed; 1 ¼ cloudy meibum expressed with mild pressure; 2 ¼ cloudy meibum expressed with more than moderate pressure; 3 ¼ meibum could not be expressed even with strong pressure. 16 Images of lid margins and orifices of meibomian glands at the upper and lower eyelids of 1 eye were obtained with a digital camera and meibography system attached to a slitlamp microscope (SL-D701 DC4 BG-5; Topcon Japan, Tokyo, Japan). 23 The images of the lid margins and those of meibomian glands were both acquired at 103 magnification for the full length of each eyelid within a single photograph. Four images (2 of each eyelid) were collected for each subject.
NEW GRADING SYSTEM: We developed grading scales for MGD with the use of printed images. All images were acquired by an ophthalmologist (R.A. or R.S.) with a specialty in MGD. Four signs for lid margin findings detected with a slit-lamp microscope and 2 signs of meibomian glands detected by meibography were selected for development of the grading scales. Three MGD experts (R.A., R.S., and S.F.), each participating at a different institution, developed draft grading scales for MGD with key conceptual components based on morphologic and anatomic criteria described in previous reviews.
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These draft grading scales were then evaluated with a preliminary validation test in which each of the 3 MGD experts classified the printed images independently according to the draft scales, and the Validation testing was performed to evaluate the robustness of the proposed grading scales after an interval of >2 weeks since their development. The raters received printed images of the upper and lower eyelids of the original 58 subjects together with printed grading scales and representative images. Each printed image had a randomly assigned number for analysis. Raters individually classified each image according to the grading scales. The test was performed by each rater at a separate site. After the test, the assigned numbers of the classified images for each grading scale were recorded for statistical analysis.
Interrater and intrarater reliability. Three MGD experts (R.A., R.S., and S.F.) performed the validation test, and consistency among their results for each grading scale was evaluated.
Two of the MGD experts who participated in the determination of interrater reliability (R.A. and S.F.) performed the test a second time after an interval of >2 weeks. Consistency between the results of the first and second tests for each grading scale was evaluated.
Effect of clinical experience. Three general ophthalmologists (non-MGD experts) who had been certified for 3, 5, or 8 years, as well as 3 non-physicians, also performed the validation test. An introduction and explanation of the grading scales were given before the test by an MGD expert (R.A.). Consistency between the results for each group of raters and those for an MGD expert (first test performance by R.A.) was evaluated as interrater reliability. 
RESULTS
THIRTY-EIGHT MGD PATIENTS (13 MEN AND 25 WOMEN;
mean age 6 SD, 66.9 6 15.0 years) and 20 control subjects (8 men and 12 women; 64.5 6 6.7 years) were eventually enrolled. All subjects underwent clinical assessment and image collection, and their clinical characteristics are shown in Table 1 .
For the MGD patients, lid margin and meibomian gland findings encompassed the range of severity levels and appeared to reflect the distribution of findings encountered in the clinic (Table 2, Figure 1 ). For the control subjects, almost all findings were normal ( Table 2) . With the exception of 6 missing images, 4 images acquired from each subject (total of 226 images) were used to develop the new grading system. NEW GRADING SYSTEM: We developed 6 grading scales for MGD based on images of the upper and lower eyelids of 38 MGD patients and 20 control subjects (Table 3 were evaluated in the full-length images of each eyelid obtained with a slit-lamp microscope. Partial glands ( Figure 6 ) and gland dropout ( Figure 7) were evaluated by noncontact meibography for meibomian glands in the middle two-thirds of each eyelid, given that it is difficult to capture and examine glands at the ends of each eyelid in a single photograph ( Figure 6 ).
Each grading scale is based on specific features. Abnormal lid margin findings of vascularity are based on 2 key components: the degree of redness at the lid margin and the distribution of telangiectasia crossing meibomian gland orifices. Plugging of gland orifices includes abnormal findings for meibomian gland orifices such as capping, pouting, and ridge and is evaluated on the basis of the number and distribution of these abnormal findings. Lid margin irregularity is evaluated on the basis of the number of lid margin irregularities and form of notching. Lid margin thickening is evaluated based on the presence of thickening and rounding. Partial glands are defined as meibomian glands showing partial loss from the orifice or fornix and are evaluated on the basis of their number and length ( Figure 6 ). Gland dropout is evaluated on the basis of the number of meibomian glands with complete loss from orifice to fornix (Figure 7) . Table 4 , referred with agreement. (Table 5) . 
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DISCUSSION
WE HAVE HEREIN DEVELOPED 6 NEW GRADING SCALES FOR typical clinical findings in MGD and have evaluated the reliability of these scales with the use of 226 images obtained from 58 subjects. The new grading scales were based on real clinical findings and were found to be robust and to show better than moderate agreement in most instances on validation testing. Whereas evaluation of dynamic features of meibomian gland function such as meibum expressibility and color is informative with regard to assessment of MGD, such evaluation is difficult to record as dynamic results. The new grading scales with representative images should thus prove helpful for the diagnosis of MGD in a consistent manner and be particularly useful for the evaluation of MGD in multicenter clinical studies.
The reliability of the new grading scales is likely attributable at least in part to the clear definitions and descriptions on which they are based, with avoidance of imprecise terms such as mild, moderate, or severe. The scales thus allow an objective classification of morphologic and anatomic findings. Moreover, the grading scales are applicable to both upper and lower eyelids. Given that the degree of morphologic change of meibomian glands has been found to differ between the upper and lower eyelids in MGD patient and dry eye patient populations, examination of both eyelids is essential for proper evaluation of the pathologic condition of such individuals. 25, 26 The new grading scales showed a high level of consistency among MGD experts, general ophthalmologists, and non-physicians. These findings indicate that any ophthalmologist should be able to diagnose MGD and classify its severity in a consistent manner with the grading scales. This ability is likely to prove especially useful in clinical studies or trials, with the grading scales allowing investigators at different sites to enroll appropriate subjects and to evaluate the efficacy of medication in a consistent manner and thus allowing the results obtained at the different sites to be compared directly.
Our evaluation of the new grading scales revealed that consistency among raters was lowest for plugging of gland orifices and lid margin irregularity. Plugging of gland orifices is usually assessed by determining the expressibility of meibum, and lid margin irregularity is usually assessed with a slit-lamp microscope by changing the angle of the light relative to the patient's eyelids. The consistent grading of these clinical findings based only on images might thus be expected to be more difficult than that for the other assessed signs.
We also investigated the diagnostic ability of the new grading scales for the enrolled MGD patients and control subjects. Construction of ROC curves and calculation of AUC values revealed that the scales for both partial glands and gland dropout showed sufficient diagnostic ability, suggesting that both signs are MGD specific and should be evaluated separately. These findings are consistent with the results of a previous study. 20 On the other hand, the AUC for abnormal lid margin findings of vascularity was lowest among the grading scales. The grading scale for this sign appears to be affected not only by MGD but also by aging or other factors, such as workplace exposure to dust particles, urban living, and cosmetics. 15 As far as we are aware, this is the first study to evaluate diagnostic ability of partial glands and gland dropout separately on the basis of AUC values. A previous study examined the diagnostic ability of the total score for 4 eyelid signs (vascular engorgement, plugged meibomian gland orifices, irregular lid margin, and anterior or posterior replacement of the mucocutaneous junction) by calculation of AUC values. 21 We evaluated the AUC for each of these signs (with the exception of mucocutaneous junction) separately. These results can provide useful information for interpretation of scores obtained with the grading scales in clinical practice.
In the present study, we evaluated only 1 eye of each subject; therefore we are unable to address the bilaterality of MGD characteristics. MGD is one of the most common causative conditions of dry eye. 27 Application of the grading scales to both eyes of an individual would provide information on the bilaterality of MGD or dry eye.
There is a general consensus regarding the definition of MGD severity based on meibum score, symptoms, and lid margin findings. 11, 14 However, the ability to evaluate MGD severity more accurately with reliable objective scales based on standardized criteria is needed. Our proposed new grading system can be used to define MGD severity. It should be possible to classify MGD patients according to disease severity with the use of such a grading system, including multiple static and dynamic evaluation procedures.
There are some limitations to the present study. First, the study was based on static evaluation of photographs and thus did not take into account dynamic observations such as meibum expressibility, including meibum quality and quantity. Given that evaluation of meibum expressibility is one of the most informative procedures regarding the pathogenesis of MGD, movie-based assessment of meibum expressibility and other dynamic features should be performed in the future. Second, the new grading scales were developed with the use of images obtained in a cross-sectional analysis. We were therefore not able to evaluate whether they are suitable for detection of changes in clinical findings. It will be necessary to confirm that the grading scales are appropriate for evaluation of medical treatment in longitudinal studies. Third, we also evaluated the reliability of the grading scales with the same set of images. Given that plugging of gland orifices and lid margin irregularity can be assessed accurately only by physical examination with observation in 3 dimensions, the assessment of these signs from 2-dimensional images may be problematic. There is thus still room for improvement of the proposed clinical scoring for MGD, but, despite its basis in static evaluation, it is potentially sufficient for clinical application. Its further improvement will be required for it to become a standard procedure for MGD diagnosis.
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